| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 110 | 2024 | 1196 | 10.260 |
Why?
|
| Graft vs Host Disease | 40 | 2024 | 540 | 4.290 |
Why?
|
| Transplantation Conditioning | 46 | 2022 | 322 | 3.910 |
Why?
|
| Multiple Myeloma | 23 | 2022 | 170 | 3.110 |
Why?
|
| Transplantation, Homologous | 45 | 2024 | 665 | 2.430 |
Why?
|
| Leukemia, Myeloid, Acute | 19 | 2021 | 538 | 2.070 |
Why?
|
| Transplantation, Autologous | 28 | 2022 | 298 | 2.010 |
Why?
|
| Myelodysplastic Syndromes | 14 | 2022 | 139 | 1.840 |
Why?
|
| Bone Marrow Transplantation | 12 | 2020 | 573 | 1.460 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2022 | 782 | 1.230 |
Why?
|
| Unrelated Donors | 15 | 2022 | 82 | 1.170 |
Why?
|
| Amyloidosis | 5 | 2020 | 71 | 0.960 |
Why?
|
| Middle Aged | 91 | 2024 | 26884 | 0.950 |
Why?
|
| Myeloablative Agonists | 10 | 2020 | 25 | 0.940 |
Why?
|
| Adult | 98 | 2024 | 29555 | 0.930 |
Why?
|
| Leukemia | 7 | 2022 | 371 | 0.900 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 6 | 2020 | 95 | 0.880 |
Why?
|
| Hematologic Neoplasms | 9 | 2021 | 283 | 0.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2022 | 1251 | 0.810 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2016 | 183 | 0.810 |
Why?
|
| Disease-Free Survival | 28 | 2022 | 897 | 0.780 |
Why?
|
| Aged | 64 | 2024 | 19830 | 0.770 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2020 | 144 | 0.750 |
Why?
|
| Humans | 158 | 2024 | 124700 | 0.740 |
Why?
|
| Male | 104 | 2024 | 61314 | 0.730 |
Why?
|
| Neoplasms, Second Primary | 8 | 2017 | 152 | 0.680 |
Why?
|
| Lymphoma, Follicular | 4 | 2017 | 30 | 0.650 |
Why?
|
| Roseolovirus Infections | 3 | 2011 | 33 | 0.640 |
Why?
|
| Herpesvirus 6, Human | 3 | 2011 | 58 | 0.630 |
Why?
|
| Female | 96 | 2024 | 66570 | 0.630 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 11 | 0.610 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 650 | 0.610 |
Why?
|
| Voriconazole | 1 | 2018 | 35 | 0.600 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 6 | 2019 | 38 | 0.600 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2019 | 224 | 0.600 |
Why?
|
| Siblings | 12 | 2022 | 197 | 0.590 |
Why?
|
| Allografts | 17 | 2021 | 190 | 0.570 |
Why?
|
| Tissue Donors | 11 | 2021 | 494 | 0.560 |
Why?
|
| T-Lymphocytes | 9 | 2024 | 1717 | 0.560 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2020 | 96 | 0.560 |
Why?
|
| Young Adult | 39 | 2024 | 9022 | 0.540 |
Why?
|
| Stem Cell Transplantation | 5 | 2022 | 237 | 0.530 |
Why?
|
| Salvage Therapy | 6 | 2021 | 192 | 0.530 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 1032 | 0.520 |
Why?
|
| Survival Analysis | 21 | 2021 | 1504 | 0.520 |
Why?
|
| Lymphoma | 5 | 2021 | 321 | 0.520 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2019 | 294 | 0.520 |
Why?
|
| Iron Overload | 2 | 2006 | 16 | 0.520 |
Why?
|
| Treatment Outcome | 41 | 2021 | 12363 | 0.510 |
Why?
|
| Adolescent | 48 | 2024 | 19216 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 5 | 2020 | 28 | 0.510 |
Why?
|
| Recurrence | 20 | 2022 | 1415 | 0.510 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1090 | 0.500 |
Why?
|
| Melphalan | 8 | 2022 | 49 | 0.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2020 | 163 | 0.480 |
Why?
|
| Heart Transplantation | 3 | 2020 | 855 | 0.450 |
Why?
|
| Skin Ulcer | 1 | 2014 | 33 | 0.450 |
Why?
|
| Thalidomide | 1 | 2014 | 36 | 0.440 |
Why?
|
| Leukemia, Myeloid | 4 | 2017 | 85 | 0.440 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 51 | 0.440 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2013 | 2 | 0.430 |
Why?
|
| Leukemoid Reaction | 1 | 2013 | 3 | 0.430 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 18 | 0.420 |
Why?
|
| Anemia, Aplastic | 3 | 2020 | 58 | 0.420 |
Why?
|
| Cytomegalovirus Infections | 3 | 2024 | 218 | 0.410 |
Why?
|
| Retrospective Studies | 30 | 2024 | 16262 | 0.400 |
Why?
|
| Incidence | 9 | 2024 | 3115 | 0.400 |
Why?
|
| Survival Rate | 17 | 2021 | 2055 | 0.400 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 1695 | 0.400 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 495 | 0.390 |
Why?
|
| Azoles | 1 | 2012 | 9 | 0.390 |
Why?
|
| Cushing Syndrome | 1 | 2012 | 16 | 0.390 |
Why?
|
| Budesonide | 1 | 2012 | 19 | 0.390 |
Why?
|
| Cyclosporine | 2 | 2019 | 147 | 0.380 |
Why?
|
| Bone Marrow | 3 | 2021 | 323 | 0.370 |
Why?
|
| HLA Antigens | 7 | 2019 | 244 | 0.370 |
Why?
|
| Bone Marrow Cells | 3 | 2021 | 263 | 0.350 |
Why?
|
| Rituximab | 6 | 2022 | 157 | 0.340 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2021 | 30 | 0.340 |
Why?
|
| Prognosis | 19 | 2021 | 4620 | 0.340 |
Why?
|
| Hodgkin Disease | 3 | 2022 | 294 | 0.330 |
Why?
|
| Child, Preschool | 22 | 2024 | 13882 | 0.320 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 292 | 0.320 |
Why?
|
| Mycophenolic Acid | 2 | 2019 | 51 | 0.310 |
Why?
|
| Graft Survival | 4 | 2012 | 536 | 0.310 |
Why?
|
| Gout | 1 | 2011 | 147 | 0.300 |
Why?
|
| Plasma Cells | 2 | 2020 | 55 | 0.290 |
Why?
|
| Alemtuzumab | 2 | 2024 | 88 | 0.290 |
Why?
|
| Graft Rejection | 2 | 2017 | 590 | 0.290 |
Why?
|
| Cytokines | 2 | 2011 | 1286 | 0.290 |
Why?
|
| Antigens, CD19 | 4 | 2018 | 177 | 0.290 |
Why?
|
| Child | 30 | 2024 | 24170 | 0.290 |
Why?
|
| Eye Diseases | 2 | 2019 | 119 | 0.280 |
Why?
|
| Antibodies, Neoplasm | 1 | 2007 | 60 | 0.270 |
Why?
|
| Paramyxoviridae Infections | 1 | 2007 | 47 | 0.270 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 21 | 0.270 |
Why?
|
| Metapneumovirus | 1 | 2007 | 51 | 0.270 |
Why?
|
| Paresis | 1 | 2006 | 34 | 0.270 |
Why?
|
| Infant | 18 | 2024 | 12381 | 0.270 |
Why?
|
| Combined Modality Therapy | 9 | 2021 | 1236 | 0.270 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 12 | 0.260 |
Why?
|
| Lymphoma, T-Cell | 1 | 2006 | 64 | 0.260 |
Why?
|
| Erythrocyte Indices | 1 | 2006 | 15 | 0.260 |
Why?
|
| Histocompatibility Testing | 5 | 2021 | 148 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 476 | 0.250 |
Why?
|
| Quality of Life | 5 | 2023 | 1936 | 0.250 |
Why?
|
| Survivors | 4 | 2019 | 337 | 0.250 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 35 | 0.250 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2005 | 14 | 0.250 |
Why?
|
| Remission Induction | 9 | 2021 | 300 | 0.240 |
Why?
|
| Cyclophosphamide | 6 | 2022 | 417 | 0.240 |
Why?
|
| Acute Disease | 8 | 2019 | 1107 | 0.240 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2005 | 62 | 0.240 |
Why?
|
| Burkitt Lymphoma | 1 | 2006 | 144 | 0.240 |
Why?
|
| Antiviral Agents | 3 | 2024 | 750 | 0.240 |
Why?
|
| Erythrocyte Transfusion | 1 | 2006 | 129 | 0.230 |
Why?
|
| Maintenance Chemotherapy | 2 | 2022 | 20 | 0.230 |
Why?
|
| Whole-Body Irradiation | 5 | 2020 | 64 | 0.230 |
Why?
|
| Busulfan | 4 | 2020 | 44 | 0.230 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2017 | 48 | 0.230 |
Why?
|
| Neutropenia | 1 | 2006 | 197 | 0.230 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 385 | 0.220 |
Why?
|
| Lymphocyte Transfusion | 2 | 2021 | 57 | 0.220 |
Why?
|
| Vancomycin | 1 | 2006 | 218 | 0.220 |
Why?
|
| Quinazolines | 1 | 2024 | 174 | 0.210 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 22 | 0.210 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2020 | 534 | 0.210 |
Why?
|
| Lung Neoplasms | 3 | 2006 | 1660 | 0.200 |
Why?
|
| Metabolic Syndrome | 2 | 2016 | 341 | 0.200 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 428 | 0.200 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 164 | 0.200 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 5154 | 0.200 |
Why?
|
| Bacterial Infections | 1 | 2005 | 308 | 0.200 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2022 | 2 | 0.190 |
Why?
|
| Liver Diseases | 1 | 2006 | 365 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2022 | 1143 | 0.190 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 1872 | 0.190 |
Why?
|
| Risk Factors | 14 | 2024 | 10249 | 0.190 |
Why?
|
| Seizures | 1 | 2006 | 870 | 0.180 |
Why?
|
| Disease Progression | 8 | 2022 | 2058 | 0.180 |
Why?
|
| Community Health Planning | 1 | 2020 | 9 | 0.180 |
Why?
|
| Body Mass Index | 5 | 2020 | 1562 | 0.170 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 184 | 0.170 |
Why?
|
| Peripheral Blood Stem Cells | 1 | 2020 | 3 | 0.170 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2020 | 34 | 0.170 |
Why?
|
| Health Information Systems | 1 | 2020 | 32 | 0.160 |
Why?
|
| Virus Integration | 2 | 2011 | 42 | 0.160 |
Why?
|
| Chronic Disease | 7 | 2021 | 1191 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 150 | 0.160 |
Why?
|
| United States | 9 | 2021 | 10866 | 0.160 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2020 | 40 | 0.160 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 124 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 539 | 0.150 |
Why?
|
| Foot Diseases | 1 | 1998 | 24 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 2 | 2019 | 675 | 0.150 |
Why?
|
| Cohort Studies | 9 | 2022 | 4799 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 356 | 0.150 |
Why?
|
| Calcineurin Inhibitors | 1 | 2018 | 29 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 86 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 726 | 0.150 |
Why?
|
| Minority Groups | 1 | 2020 | 248 | 0.150 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 15 | 0.150 |
Why?
|
| Registries | 3 | 2020 | 1428 | 0.150 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 1437 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2018 | 98 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 130 | 0.140 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 872 | 0.140 |
Why?
|
| Donor Selection | 1 | 2018 | 55 | 0.140 |
Why?
|
| Leukemic Infiltration | 1 | 1997 | 9 | 0.140 |
Why?
|
| Poverty | 1 | 2021 | 421 | 0.140 |
Why?
|
| Viral Load | 1 | 2019 | 383 | 0.140 |
Why?
|
| Neoplasms | 3 | 2021 | 2780 | 0.140 |
Why?
|
| Antigens, CD34 | 3 | 2020 | 108 | 0.140 |
Why?
|
| Osteonecrosis | 2 | 2014 | 11 | 0.140 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 6584 | 0.140 |
Why?
|
| Cervix Uteri | 1 | 1997 | 64 | 0.140 |
Why?
|
| Neoplasm Staging | 4 | 2018 | 1277 | 0.140 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 1399 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 402 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 397 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 23 | 0.130 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 31 | 0.130 |
Why?
|
| Methotrexate | 1 | 2018 | 337 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 472 | 0.130 |
Why?
|
| Hospitals, Special | 1 | 2015 | 13 | 0.130 |
Why?
|
| Janus Kinase 1 | 1 | 2015 | 12 | 0.130 |
Why?
|
| Filgrastim | 3 | 2015 | 15 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2018 | 288 | 0.130 |
Why?
|
| Databases, Factual | 5 | 2021 | 1176 | 0.130 |
Why?
|
| Biopsy | 2 | 2012 | 1234 | 0.120 |
Why?
|
| Ferritins | 2 | 2006 | 98 | 0.120 |
Why?
|
| Cytomegalovirus | 3 | 2024 | 269 | 0.120 |
Why?
|
| DNA, Viral | 2 | 2007 | 480 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 26 | 0.120 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 1357 | 0.120 |
Why?
|
| Sarcoma, Myeloid | 1 | 2015 | 12 | 0.120 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 31 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 36 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 101 | 0.120 |
Why?
|
| Caspase 9 | 1 | 2015 | 75 | 0.120 |
Why?
|
| Blood Donors | 3 | 2020 | 62 | 0.120 |
Why?
|
| Treatment Failure | 4 | 2020 | 335 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 62 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2017 | 197 | 0.110 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 131 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2020 | 6132 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2417 | 0.110 |
Why?
|
| Bortezomib | 3 | 2022 | 72 | 0.110 |
Why?
|
| Social Class | 1 | 2015 | 190 | 0.110 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2016 | 121 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 1958 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2014 | 683 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 330 | 0.110 |
Why?
|
| Time Factors | 6 | 2019 | 6323 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2017 | 454 | 0.110 |
Why?
|
| Mass Screening | 2 | 2018 | 772 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 185 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 420 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2015 | 359 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 378 | 0.100 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2013 | 28 | 0.100 |
Why?
|
| Fetal Blood | 2 | 2022 | 176 | 0.100 |
Why?
|
| Dexamethasone | 2 | 2022 | 276 | 0.100 |
Why?
|
| Fertility Preservation | 1 | 2013 | 52 | 0.100 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 73 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 816 | 0.100 |
Why?
|
| Age Factors | 5 | 2017 | 2807 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2014 | 266 | 0.090 |
Why?
|
| Colchicine | 1 | 2011 | 44 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 79 | 0.090 |
Why?
|
| Cause of Death | 3 | 2021 | 474 | 0.090 |
Why?
|
| Chromosomes, Human | 1 | 2011 | 130 | 0.090 |
Why?
|
| Autografts | 3 | 2015 | 27 | 0.090 |
Why?
|
| Carmustine | 2 | 2022 | 26 | 0.090 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 133 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 255 | 0.090 |
Why?
|
| CD28 Antigens | 1 | 2011 | 79 | 0.090 |
Why?
|
| Cytarabine | 2 | 2022 | 98 | 0.090 |
Why?
|
| Allopurinol | 1 | 2011 | 71 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 533 | 0.090 |
Why?
|
| Steroids | 1 | 2011 | 201 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 1052 | 0.090 |
Why?
|
| Etoposide | 3 | 2020 | 114 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 139 | 0.080 |
Why?
|
| Arsenicals | 1 | 2009 | 14 | 0.080 |
Why?
|
| Oxides | 1 | 2009 | 15 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2009 | 47 | 0.080 |
Why?
|
| Pyrazines | 1 | 2009 | 75 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 129 | 0.080 |
Why?
|
| Karyotyping | 2 | 2006 | 323 | 0.070 |
Why?
|
| Depression | 1 | 2017 | 1236 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 336 | 0.070 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 2900 | 0.070 |
Why?
|
| Sex Factors | 3 | 2018 | 1287 | 0.070 |
Why?
|
| Chromosome Aberrations | 2 | 2021 | 612 | 0.070 |
Why?
|
| Vidarabine | 2 | 2020 | 79 | 0.070 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 23 | 0.070 |
Why?
|
| Heart Failure | 1 | 2020 | 2297 | 0.070 |
Why?
|
| Myocardium | 1 | 2012 | 1019 | 0.070 |
Why?
|
| Vincristine | 2 | 2006 | 191 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 5845 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 846 | 0.070 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2006 | 14 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 265 | 0.070 |
Why?
|
| Epoetin Alfa | 1 | 2006 | 10 | 0.070 |
Why?
|
| Cell Count | 2 | 2019 | 254 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2006 | 63 | 0.070 |
Why?
|
| Darbepoetin alfa | 1 | 2006 | 15 | 0.070 |
Why?
|
| Hematopoietic System | 1 | 2006 | 7 | 0.070 |
Why?
|
| Phlebotomy | 1 | 2006 | 16 | 0.070 |
Why?
|
| Drug Resistance | 2 | 2018 | 257 | 0.060 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2006 | 23 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 41 | 0.060 |
Why?
|
| Transferrin | 1 | 2006 | 50 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2006 | 290 | 0.060 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2006 | 24 | 0.060 |
Why?
|
| Pancreatic Diseases | 1 | 2006 | 38 | 0.060 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2005 | 6 | 0.060 |
Why?
|
| Bone Marrow Diseases | 1 | 2006 | 41 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2006 | 106 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2006 | 231 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 431 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2005 | 66 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2006 | 129 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2005 | 142 | 0.060 |
Why?
|
| Pituitary Neoplasms | 1 | 2005 | 80 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 120 | 0.060 |
Why?
|
| Acetates | 1 | 2024 | 74 | 0.060 |
Why?
|
| Tumor Virus Infections | 1 | 2005 | 135 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2005 | 119 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2006 | 312 | 0.050 |
Why?
|
| Retroviridae | 2 | 2016 | 197 | 0.050 |
Why?
|
| Iron | 1 | 2006 | 270 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1578 | 0.050 |
Why?
|
| Down Syndrome | 1 | 2006 | 198 | 0.050 |
Why?
|
| Karnofsky Performance Status | 2 | 2015 | 12 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 3444 | 0.050 |
Why?
|
| North America | 1 | 2023 | 239 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2016 | 329 | 0.050 |
Why?
|
| International Cooperation | 2 | 2014 | 156 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2005 | 214 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 512 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 505 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2005 | 330 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 265 | 0.050 |
Why?
|
| Antilymphocyte Serum | 1 | 2022 | 56 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2023 | 217 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 66 | 0.050 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 58 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2005 | 366 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 1151 | 0.040 |
Why?
|
| Blast Crisis | 1 | 2020 | 17 | 0.040 |
Why?
|
| Marital Status | 1 | 2020 | 32 | 0.040 |
Why?
|
| Ifosfamide | 2 | 2018 | 30 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 80 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 762 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 123 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 239 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1327 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 2161 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 45 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3292 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2248 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 121 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2018 | 8162 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 13 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 1997 | 352 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2016 | 759 | 0.040 |
Why?
|
| Liver | 1 | 2006 | 1742 | 0.040 |
Why?
|
| Medicaid | 1 | 2021 | 242 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 259 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 410 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 89 | 0.040 |
Why?
|
| Carboplatin | 1 | 2018 | 76 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 79 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 61 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 1997 | 49 | 0.030 |
Why?
|
| Pericardial Window Techniques | 1 | 1996 | 6 | 0.030 |
Why?
|
| Probability | 1 | 2017 | 321 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 217 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 1996 | 64 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 238 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 522 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 990 | 0.030 |
Why?
|
| Karyotype | 1 | 2015 | 28 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 124 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2015 | 70 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2015 | 59 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 175 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 136 | 0.030 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2015 | 48 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 248 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 251 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 235 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 1290 | 0.030 |
Why?
|
| Income | 1 | 2015 | 133 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 130 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 541 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 369 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 822 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 143 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 428 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 1 | 2013 | 15 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2885 | 0.030 |
Why?
|
| Ganglioneuroma | 1 | 1993 | 18 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 522 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 73 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 327 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2015 | 445 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 503 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 2511 | 0.030 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1993 | 71 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 802 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3415 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1493 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1997 | 938 | 0.020 |
Why?
|
| Anesthesia | 1 | 2015 | 207 | 0.020 |
Why?
|
| Palliative Care | 1 | 1996 | 429 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 1530 | 0.020 |
Why?
|
| Pain | 1 | 2015 | 450 | 0.020 |
Why?
|
| Cataract | 1 | 2014 | 224 | 0.020 |
Why?
|
| Infertility | 1 | 2013 | 76 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 274 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 285 | 0.020 |
Why?
|
| Graft vs Tumor Effect | 1 | 2011 | 7 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 752 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 381 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1896 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 606 | 0.020 |
Why?
|
| Premedication | 1 | 2009 | 42 | 0.020 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2009 | 8 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1260 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2009 | 85 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 304 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 765 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 229 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 697 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1561 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 1022 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 628 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 220 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2006 | 37 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2011 | 675 | 0.020 |
Why?
|
| Ribavirin | 1 | 2005 | 79 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2005 | 229 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1291 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2092 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 3714 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1693 | 0.010 |
Why?
|
| Pregnancy | 1 | 2012 | 7171 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 3561 | 0.010 |
Why?
|
| Cisplatin | 1 | 1993 | 249 | 0.010 |
Why?
|